Peripheral in Biological Technology

NeurogesX Reports Second Quarter 2009 Results

... (EC) approval of Qutenza for treatment of peripheral neuropathic pain in non-diabetic adults, either ... all 27 EU-member countries for the treatment of peripheral neuropathic pain in non-diabetic adults, either ... safety study in on-label indications of peripheral neuropathic pain in non-diabetic adults, either ...

Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009

... that Cook's Zilver(TM) paclitaxel-eluting peripheral stent may contribute additional royalty revenue ... treated with Cook's ZILVER PTX paclitaxel-eluting peripheral stent were free from reintervention at two-year ... safety and efficacy of the ZILVER PTX in treating peripheral artery disease. The most recent results were ...

FlowCardia, Inc. Appoints Chris Barys to Chief Operating Officer

... as Vice President of Sales and Marketing for the peripheral Vascular Systems business for Edwards ... device space. The novel CROSSER Catheter enables peripheral and coronary interventionalists to recanalize ... blockage in the central lumen of the coronary or peripheral artery. Once the CROSSER Catheter passes through ...

IDEV Technologies Names Veteran Medical Device Executive Rick Anderson Chairman of the Board of Directors

... the FDA-approved SUPERB (Comparison of the SUPERA peripheral System to a Performance Goal Derived from Balloon ... designed for the treatment of biliary and peripheral artery disease in the superficial femoral artery. ... millions of patients who suffer from biliary and peripheral vascular disease. This is a strong company with ...

Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association

... appears to avoid the off-target effects, such as peripheral neuropathy, associated with currently available ... reported include anemia and fatigue. No cases of peripheral neuropathy, a common adverse event associated ... the lack of overlapping toxicities and absence of peripheral neuropathy may allow for long-term dosing - and ...

NeurogesX Receives European Commission Approval for Qutenza(TM)

... Approved for peripheral neuropathic pain in non-diabetic adults SAN ... patch (formerly NGX-4010) for the treatment of peripheral neuropathic pain in non-diabetic adults either ... capsaicin and to provide sustained relief from peripheral neuropathic pain. Following application to the ...

NeurogesX Reports First Quarter 2009 Results

... Qutenza(TM) (formerly NGX-4010) for treatment of peripheral neuropathic pain in non-diabetic adults, either ... (MAA) for Qutenza for the treatment of peripheral neuropathic pain in non-diabetic adults, either ... supported by the proposed broad E.U. label for peripheral neuropathic pain conditions in non-diabetic ...

NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results

... therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic ... patch designed to manage pain associated with peripheral neuropathic pain conditions. NeurogesX submitted ... recommending approval for the treatment of peripheral neuropathic pain in non-diabetic adults alone or ...

NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting

... of Postherpetic Neuralgia and Painful Diabetic peripheral Neuropathy on Health Care Costs," summarized the ... for Human Use (CHMP) recommending approval for peripheral neuropathic pain in non-diabetic adults either ... of Postherpetic Neuralgia and Painful Diabetic peripheral Neuropathy on Health Care Costs," presented by ...

CeNeRx BioPharma Awarded New Patent for its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors

... its novel compounds that selectively target peripheral cannabinoid receptors. By avoiding the CNS, ... preclinical compounds that selectively target peripheral CB1 and CB2 cannabinoid receptors. The company ... designed so their activity is restricted to the peripheral nervous system, with minimal or no central ...

NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update

... (formerly NGX-4010), for the treatment of peripheral neuropathic pain in non-diabetic adults either ... therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic ... patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company ...

NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union

... Broad Label Indicated for peripheral Neuropathic Pain in Non-Diabetic Adults ... (formerly NGX-4010), for the treatment of peripheral neuropathic pain in non-diabetic adults either ... rapid, localized and sustained relief from peripheral neuropathic pain. The CHMP's positive ...

Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida

... a multi-center Phase I/II clinical trial in peripheral arterial disease patients and a Phase I trial in ... attack, as well as chronic conditions such as peripheral arterial and vascular disease, cardiovascular ... safety and efficacy study of TSC in peripheral arterial disease patients suffering from ...

NeurogesX to Present at 11th Annual BIO CEO & Investor Conference

... therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic ... patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company ... FDA and an MAA for Qutenza seeking approval for peripheral neuropathic pain is currently under review by the ...

Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant

... study of 6R-BH4 in patients with symptomatic peripheral arterial disease (PAD). There was no statistical ... on PWT. Endothelial dysfunction evaluated by peripheral arterial tonometry in a subset of patients did ... at baseline. 6R-BH4 was well-tolerated in peripheral arterial disease patients and had a safety ...

ev3 Inc. Receives FDA Clearance to Market EverCross and NanoCross Peripheral Angioplasty Balloons

... market its EverCross 0.035" and NanoCross 0.014" peripheral angioplasty balloon catheters. ev3 expects to ... commercialization of the EverCross and NanoCross peripheral balloon catheters globally in January 2009. ... product. The ability to offer our own peripheral balloon catheter also provides access to key ...

Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology

... associated with a low incidence of peripheral neuropathy, a common side effect associated with ... bortezomib. Exacerbation of pre-existing peripheral neuropathy was rare and did not result in dose ... reported. No treatment-emergent Grade 3 or 4 peripheral neuropathy was reported in this study. ....

Resverlogix Board of Directors Update

... disease, vascular dementia, stroke, and peripheral Artery Disease (PAD). ApoA-I, the critical ... cholesterol transport (RCT), the transport of peripheral cholesterol including that of the vessel wall to ... coronary syndrome, diabetes, Alzheimer's disease, peripheral Artery Disease and other vascular disorders. The ...

Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601

... in diabetics with mild to moderate diabetic peripheral sensory motor neuropathy in the legs. 110 ... in a distribution pattern that targets the major peripheral nerves in the legs and feet. The symptoms of diabetic peripheral neuropathy and any changes that occur during the ...

NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference

... therapies. Its initial focus is on chronic peripheral neuropathic pain, including ... patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company ... (MAA) for NGX-4010 seeking approval for peripheral neuropathic pain is currently under review by the ...

NeurogesX Reports Third Quarter 2008 Results

... MAA under review for NGX-4010 in peripheral neuropathic pain SAN MATEO, Calif., Nov. 6 ... scheduled Day 120 questions regarding our MAA for peripheral neuropathic pain. NGX-4010 has the potential to ... therapies. Its initial focus is on chronic peripheral neuropathic pain, including ...

ev3 Inc. Reports Third Quarter 2008 Financial Results

... System offers as a front-line therapy in treating peripheral artery disease. In addition, interest in ... European DURABILITY I clinical study, a landmark peripheral stent study covering the longest lesion lengths ... artery lesions. Sales Review peripheral vascular segment product sales in the third ...

NeurogesX to Report Third Quarter 2008 Financial Results

... therapies. Its initial focus is on chronic peripheral neuropathic pain, including ... patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company ... (MAA) for NGX-4010 seeking approval for peripheral neuropathic pain is currently under review by the ...

European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fibromyalgia

... of major depressive disorder and diabetic peripheral neuropathic pain in many countries, and is ... headache, insomnia, diarrhoea -- For diabetic peripheral neuropathic pain: Nausea, somnolence ... Cymbalta, and market the product for diabetic peripheral neuropathic pain as Ariclaim(R). In Greece, ...

Boston Scientific Announces Results for Third Quarter Ended September 30, 2008

... $694 $740 (6%) (9%) peripheral INTERVENTION 143 147 ... 88 81 7% 2% peripheral EMBOLIZATION 23 25 ... $2,158 $2,257 (4%) (9%) peripheral INTERVENTION 452 445 1% ...

Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System

... body temperature control, eliminating the use of peripheral temperature probes which are generally slow to ... body temperature control, eliminating the use of peripheral temperature probes which are generally slow in ... (cardiovascular ischemia, peripheral arterial disease) and orthopedic products, ...

Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008

... outcomes in patients suffering from lower limb peripheral arterial disease (PAD). The presentation, ... the incidence of restenosis in PAD." About peripheral Arterial Disease peripheral artery disease, or PAD, is characterized by fatty ...

NeurogesX Responds to EMEA's Day 120 Questions

... Authorization Application (MAA) for NGX-4010 in peripheral neuropathic pain. NeurogesX' MAA for NGX-4010 in peripheral neuropathic pain was accepted for review by the ... therapies. Its initial focus is on chronic peripheral neuropathic pain, including ...

Vermillion and Stanford Scientists Receive 'Best Research Award' From the PAD Coalition

... the morbidity and mortality associated with peripheral Artery Disease. Vermillion has entered into an ... in making the test widely available. About peripheral Artery Disease (PAD) PAD, a serious but often ... buildup of fat and cholesterol, or plaque, in the peripheral arteries, disrupting normal blood flow. ...

Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL

... trial in patients with relapsed or refractory peripheral T-cell lymphoma who have failed at least one ... with recurrent or refractory cutaneous (CTCL) or peripheral T-cell lymphoma (PTCL). Efficacy is being ... trials as a potential treatment for cutaneous and peripheral T-cell lymphomas, B-cell lymphomas, ...

Limbs saved by menstrual blood stem cells

... blood flow in an animal model of advanced peripheral artery disease. A study published today in BioMed ... Critical limb ischemia, an advanced form of peripheral artery disease, causes approximately 150,000 ... trials with adult stem cells for patients with peripheral artery disease. He stated, "The advantage of ERCs ...

NeurogesX Reports Second Quarter 2008 Results

... application under review for NGX-4010 in peripheral neuropathic pain - ... therapies. Its initial focus is on chronic peripheral neuropathic pain, including ... patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company ...

Chest Physicians Now Suggest Early Intervention for Certain Blood Clots in DVT

... Will Increase Use of Trellis(R) peripheral Infusion System NORTHBROOK, Ill., July 29 ... device company dedicated to the treatment of peripheral vascular disease. Dr. Thomas Fogarty, a noted ... vision of transforming blood clot removal from peripheral blood vessels into a fast, simple, ...

Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children

... comfort when performing the numerous peripheral venous access procedures that occur each day. ... of the patients served in these hospitals undergo peripheral venous access procedures repeatedly, and are ... that approximately 18 million pediatric peripheral venous access procedures are performed annually ...

Angiotech's corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study

... PTX drug-eluting peripheral stent in treating peripheral arterial disease (PAD). The results, which were ... trial data for the Zilver PTX paclitaxel-eluting peripheral stent," said Dr. William Hunter, President and ... upon the commercial sale of paclitaxel-eluting peripheral vascular stent products, including the ....

Oxford Finance Corporation and ATEL Ventures, Inc. Provide $7.5 Million Venture Loan to AxoGen, Inc.

... AxoGen is a leader in the advancement of peripheral nerve repair. Their patented product, AVANCE(TM) ... by surgeons for the repair and regeneration of peripheral nerves. "Oxford's and ATEL's support will allow ... to improve the standard of care for patients with peripheral nerve injuries," said Jamie Grooms, AxoGen chief ...

NeurogesX Opens Investigational New Drug Application for Capsaicin Liquid Formulation NGX-1998

... to evaluate potential controls for studies in peripheral neuropathic pain. About NeurogesX, Inc. ... therapies. Its initial focus is on chronic peripheral neuropathic pain, including ... patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company ...

Peripheral Vascular Device Market Insights Webinar

... Mass., June 2 /PRNewswire/ -- WHAT: peripheral VASCULAR DEVICE MARKET INSIGHTS WEBINAR ... Webinar outlining our knowledge of the peripheral vascular (PV) device industry. Sign up to gain information derived from our Global peripheral Vascular Device report series and PV ...

FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults

... for Zingo to treat pain associated with peripheral IV insertions and blood draws in ... by the FDA to provide local analgesia prior to peripheral IV insertions and blood draws in children three ... a hospital. In 2004, more than 245 million adult peripheral venous access procedures and more than 18 ...

Volcano Announces Acquisition of Novelis, Inc.

... the diagnosis and treatment of coronary and peripheral vascular disease, said today that it has acquired ... including plaque modification in the coronary or peripheral arteries, guidance in structural heart ... and therapeutic applications in the coronary and peripheral arteries, including the treatment of CTOs. It ...